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Background: Schizophrenia has a large genetic component, and the pathways from genes to 
illness manifestation are beginning to be identified. The Genetics of Endophenotypes of 
Neurofunction to Understand Schizophrenia (GENUS) Consortium aims to clarify the role of 
genetic variation in brain abnormalities underlying schizophrenia. This article describes the 
GENUS Consortium sample collection. 
Methods: We identified existing samples collected for schizophrenia studies consisting of 
patients, controls, and/or high-risk individuals with a family history of schizophrenia. Samples 
had single nucleotide polymorphism (SNP) array data or genomic DNA, clinical and 
demographic data, and neuropsychological and/or brain magnetic resonance imaging (MRI) 
data. Data were subjected to quality control procedures at a central site.  
Results: Sixteen research groups contributed data from 5,155 psychosis patients, 4,832 
controls, and 725 familial high-risk (FHR) individuals. All participants have relevant demographic 
data; all patients have relevant clinical data. The sex ratio is 57% male and 43% female. 
Significant differences exist between diagnostic groups for premorbid and current IQ (both 
p<1x10-10). Data from a diversity of neuropsychological tests are available for 93% of 
participants, and 30% have structural MRI scans (half also have diffusion-weighted MRI scans). 
SNP data are available for 75% of participants. The ancestry composition is 71% European, 
19% East Asian, 7% African, and 3% other.  
Conclusions: The GENUS Consortium is investigating the genetic contribution to brain 
phenotypes in a schizophrenia sample collection of >10,000 participants. The breadth of data 
across clinical, genetic, neuropsychological, and MRI modalities provides an excellent 











Clinical presentation of schizophrenia varies among individuals, but in general is characterized 
by positive (hallucinations, delusions), negative (social withdrawal), and disorganization 
symptoms, cognitive impairments, altered brain structure and function, and severe deficits in 
global and social functioning. There is a generalized cognitive impairment, as well as specific 
deficits across cognitive domains including processing speed, attention, working memory, verbal 
memory, and executive functioning, that are present as early as the pre-morbid state during 
childhood and persist through chronic stages of illness (Lewandowski et al., 2011; Seidman and 
Mirsky, under review). There is consistent evidence from schizophrenia neuroimaging studies 
for ventricular enlargement, reduced gray matter volume of cortical and subcortical brain 
regions, and reduced white matter volume and fractional anisotropy of predominantly fronto-
temporal tracts (Bora et al., 2011; Haijma et al., 2013; Shenton et al., 2001; van Erp et al., 
2016). Unaffected relatives of schizophrenia patients exhibit milder cognitive deficits and brain 
structural abnormalities (Boos et al., 2007; Keshavan et al., 2010; Thermenos et al., 2013), 
suggesting these abnormalities are risk factors for the disorder rather than secondary effects. 
The molecular mechanisms underlying these brain abnormalities are only beginning to be 
unraveled, which has hindered the identification of rational targets for developing better 
treatments. 
A practical approach for elucidating the disease biology is identifying genes that confer 
risk and characterizing their function within the brain. It is long known that schizophrenia has a 
large genetic component, with heritability between 64-81% (Lichtenstein et al., 2009; Sullivan et 
al., 2003). Genome wide association studies (GWAS) of schizophrenia case/control datasets by 
the Psychiatric Genomics Consortium (PGC) have identified over 100 chromosomal loci that 
have genome-wide significant evidence for association (PGC Schizophrenia Working Group, 
2014). GWAS results indicate that schizophrenia is a polygenic disorder, for which thousands of 
common genetic variants with modest individual effects act in aggregate to increase disease 
liability (Psychosis Endophenotypes International Consortium et al., 2014; Purcell et al., 2009; 
Ripke et al., 2013). Rare variants further contribute to schizophrenia liability (CNV and 
Schizophrenia Working Groups of the Psychiatric Genomics Consortium; Psychosis 
Endophenotypes International Consortium, 2017; Malhotra and Sebat, 2012). 
A promising approach to translate these genetic findings into an understanding of the 
neural processes involved in schizophrenia is to evaluate their relevance to disease 
endophenotypes (Gottesman and Gould, 2003). In this context, cognitive measures have a 
moderate to high heritability (h2 = 0.2-0.7) (Seidman et al., 2015; Stone and Seidman, 2016), 
while volumetric and diffusion brain measures are highly heritable (h2 = 0.6-0.8) (Blokland et al., 
2012; 2016). Common genetic variation (based on SNPs) explains a substantial proportion of 
this heritability, estimated at h2 = 0.3-0.4 for cognitive (Hatzimanolis et al., 2015; Robinson et al., 
2015) and brain volume phenotypes (Ge et al., 2015). Moderate to high genetic correlations 
between schizophrenia and cognitive and brain structural phenotypes (rg = 0.5-0.8) suggest a 
partially shared genetic etiology (Blokland et al., 2016; Bohlken et al., 2016; Lee et al., 2016). 
Indeed, polygenic risk for schizophrenia is significantly associated with prefrontal inefficiency 
during working memory performance in patients and controls (Walton et al., 2013a; Walton et 
al., 2013b), as well as lower cognitive performance among healthy populations (Germine et al., 
2016; Hubbard et al., 2016; Lencz et al., 2014; Liebers et al., 2016) and schizophrenia patients 
(Martin et al., 2015). Specific genetic risk variants have also been associated with altered 
cognition and brain structure among patients (Donohoe et al., 2010; 2013; Lencz et al., 2010; 
Martin et al., 2015; Wassink et al., 2012; Yeo et al., 2014) although some studies are negative 
(van Scheltinga et al., 2013), possibly due to the use of small samples that are prone to 
inconsistent results. Analyses of large, well-phenotyped samples consisting of both psychosis 
patients and control individuals will be important for clarifying the role of genetic risk variants in 
brain abnormalities relevant to illness.  
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With this in mind, the GENUS Consortium aims to improve knowledge of the contribution 
of genetic variation to schizophrenia brain abnormalities by investigating relevant brain traits in a 
large, comprehensively phenotyped sample collection. The GENUS Consortium draws upon the 
efforts of sixteen research groups that have previously collected samples consisting of 
psychosis patients (predominantly schizophrenia), unaffected controls, and/or unaffected 
familial high-risk (FHR) individuals assessed for neuropsychological function and/or brain 
structure, all of which have genome-wide SNP data or genomic DNA. Assembly of these 
samples into one harmonized collection substantially increases the statistical power compared 
to the individual samples alone. The large, well-phenotyped GENUS sample collection provides 
a prime opportunity to investigate the genetic basis of brain abnormalities in psychosis in order 
to gain insight into the underlying neural mechanisms. The purpose of this article is to describe 
the design, composition, and data components of the sample collection, while subsequent 
articles will focus on data analyses. 
 
2. Methods 
2.1. Collection of samples 
Research groups that had previously collected samples for the purpose of schizophrenia studies 
were identified from the psychiatric genetics community and publications. Criteria for inclusion 
were: availability of SNP genotype data or genomic DNA, as well as demographic, 
neuropsychological and/or magnetic resonance imaging (MRI) data, and, for patients, clinical 
data.  
2.2. Informed consent and ethics approval 
The lead principal investigator for each sample verified approval from their institutional ethics 
committee for sharing human subject data. All research participants provided written informed 
consent (or legal guardian consent and subject assent). Ethics approval for the GENUS 
Consortium study at the central site was obtained from the Partners Healthcare (USA) 
Institutional Review Board. All data were anonymized prior to transfer to the central site. 
2.3. Clinical and demographic data 
For demographic data, all research groups had collected data on age at recruitment, sex, and 
education level, and most groups had also collected data on socioeconomic status and 
handedness. Clinical data were available for patients and, for some samples, FHR individuals. 
All site-specific clinical variables were renamed according to a common variable naming 
convention. Raw data underwent quality control analyses at the central site for expected value 
ranges and outliers. To enable comparison across sites, we computed basic descriptives 
(means and standard deviations for quantitative variables; frequency tables for categorical 
variables) and plotted histograms to check for unexpected differences in data distributions. 
Antipsychotic medication dosages, both current and lifetime, where available, were converted to 
chlorpromazine equivalents based on published dosage equivalence estimates (Gardner et al., 
2010; Woods, 2003).  
2.4. Neuropsychological data 
The specific neuropsychological tests ranged across samples, although all research groups 
administered tests within the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) consensus cognitive battery (Nuechterlein et al., 2008) or tests with 
similar design and scoring. We therefore focused on MATRICS tests and tests that measure 
similar cognitive constructs as the MATRICS tests. Additionally, we included visuospatial ability 
and verbal ability tests, as most groups administered these tests. All site-specific test variables 
were renamed according to a common variable naming convention. The raw data from each test 
were checked for errors by calculating descriptive statistics and visualizing data distributions for 
each study sample. Premorbid IQ was estimated from reading tests (or vocabulary if reading 
 6 
tests were not available), and current IQ from Wechsler Adult Intelligence Scale (WAIS) 
subtests (see Supplementary Materials). 
2.5. Neuroimaging data 
For those research groups that acquired MRI scans, we required 1.5 or 3 Tesla field strength, 
and availability of control scans in order to normalize the imaging data. We imposed no 
restrictions on the scanner vendor or model. As an initial assessment of quality, a subset of 12 
scans from each sample (3 male patients, 3 female patients, 3 male controls, 3 female controls) 
were visually inspected for consistent artifacts using 3DSlicer (http://www.slicer.org; Fedorov et 
al., 2012), including partial brain coverage, wrap-around and motion artifacts, and gross 
signal/contrast inhomogeneity. Further quality control analyses were carried out upon receipt of 
the full dataset and will be described elsewhere.  
2.6. SNP genotype data 
Each research group provided raw SNP array genotype data, when available, or genomic DNA 
extracted from whole blood, buffy coat or saliva (≥2 ng/μL) that we genotyped on the Illumina 
Infinium PsychArray. Although most participants had self-reported ancestry information, we 
assigned ancestry by merging genotype call data from each sample with the 1000 Genomes 
Reference Panel (Sudmant et al., 2015; The 1000 Genomes Project Consortium et al., 2015), 
and applying multidimensional scaling using Plink software (Purcell et al., 2007) to extract 
ancestry principal components. Model-based clustering (R function ‘Mclust’) was applied to 
classify participants into ancestral populations as defined by the 1000 Genomes Reference 
Panel. Basic quality control analyses of raw genotype data consisted of removing unplaced 
SNPs and confirming consistency between reported sex and X chromosome genotype. 
2.7. Statistical analyses 
Quantitative demographic data from patient, control, and FHR groups were compared using 
ANOVA. Chi-square tests compared the relative proportions of males/females, ancestral 
populations, and handedness across groups. For all statistical tests, an uncorrected alpha of 
0.05 was applied. 
 
3. Results 
3.1. Central data management  
Sixteen research groups contributed data from 19 samples consisting of 5,155 patients, 4,832 
controls, and 725 FHR participants (unaffected relatives of psychosis patients), totaling 10,712 
participants. Table 1 lists the data from each sample that was provided to the central site 
(Massachusetts General Hospital). Details for each data modality are provided in the sections 
below. Each research group provided the central site with detailed sample information (see 
Supplementary Materials), including recruitment (source, target diagnosis, illness stage [e.g. 
first-episode sample]), inclusion/exclusion criteria (ranges of age, IQ, and years of education; 
substance and medication use, MRI contraindications), and data modalities, which the central 
site reviewed and obtained clarification as necessary. Some samples have been previously 
contributed to other research consortia or the data made available in repositories (see 
Supplementary Materials). 
 
3.2. Demographic and clinical characteristics of samples 
Table 2 shows the demographic and clinical characteristics of the 19 samples. The patient 
diagnoses consist of 78.9% schizophrenia, 8.8% schizoaffective disorder (SAD), 1.8% 
schizophreniform disorder (SPD), 6.6% bipolar disorder with psychosis (BD), and 4.0% other 
psychoses. 
Fourteen samples consist of controls and patients with a range of illness durations, 
except for one sample (GAP) consists of only first-episode patients and controls. Four of these 
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14 samples also contain FHR individuals. Two samples consist of FHR and controls, two 
samples consisted of only patients, and one sample consists of only controls. Given the range 
of illness duration (0-58 years) and the inclusion of FHR participants, the sample collection has 
a wide age range (8-86 years). The sex composition is 57% male and 43% female. There are 
significant differences between the patient, control, and FHR groups in age (younger FHR), sex 
ratio (more male patients), years of education (fewer in patients), and ancestral population (all 
p<1x10-10; Table 2), but not in handedness. These differences must be adjusted in analyses, or 
matched subsets selected. 
The most common clinical data across the samples are the Positive and Negative 
Syndrome Scale (PANSS; 54.4% of patients) (Kay et al., 1987; Peralta and Cuesta, 1994), 
Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1983) and Scale for the 
Assessment of Positive Symptoms (SAPS) (Andreasen, 1984) (41.9% of patients), and Global 
Assessment of Functioning (GAF; 33.9% of patients) (American Psychiatric Association, 2000).  
Current or lifetime average dose of antipsychotic medication (chlorpromazine 
equivalents) (Gardner et al., 2010; Woods, 2003) is available for 58.2% or 26.0% of patients, 
respectively, and 20.4% of patients have both dosage estimates. Dosages are similar to other 
clinical samples (Eum et al., 2017; van Erp et al., 2016), suggesting that this patient collection is 
representative of and generalizable to the clinical population. 
3.3. Neuropsychological measures 
All 19 samples have neuropsychological data from 4,865 patients (78.2% schizophrenia, 9.3% 
SAD, 1.7% SPD, 6.9% BD, 4.0% other psychosis), 4,368 controls, and 723 FHR individuals 
(9,956 participants or 93% of sample; Table 1). The most common tests administered across 
the samples are shown in Table 3, with highest overlap across samples for Digit Symbol 
Coding, Verbal Fluency, and Word List Learning. Supplementary Table 3 provides detailed 
information on the specific tests and number of participants. There are substantial differences in 
the mean premorbid IQ and mean current IQ between diagnostic groups (both p<1x10-10; Table 
2). The mean premorbid and current IQ of controls and FHR individuals are higher than the 
population mean of 100, as previously reported by other psychosis studies (Hill et al., 2013; 
Seidman et al., 2015). However, the difference of ~10 IQ points between the GENUS patients 
and controls is consistent with the literature (Khandaker et al., 2011; Woodberry et al., 2008). 
Among the controls, current IQ is notably higher than premorbid IQ. The high current IQ is 
predominantly driven by samples that used few (2-4) WAIS subtests, which may overestimate 
current IQ compared to samples that used many subtests (i.e., full-scale IQ) (Axelrod, 2002). 
The higher current IQ may also be due to a ceiling effect, where the reading tests used to 
estimate premorbid IQ have a lower maximum score (~130) than WAIS subtests used to 
estimate current IQ (maximum 160). 
3.4. Neuroimaging data 
Thirteen samples have T1-weighted structural MRI scans from 1,343 patients (78.6% 
schizophrenia, 8.0% SAD, 3.9% SPD, 5.4% BD, 4.2% other psychosis), 1,502 controls, 370 
FHR individuals (3,215 participants or 30% of sample; Table 1). Quality evaluation of a subset 
of scans from each sample discounted systematic gross errors and indicated that all datasets 
are high quality. In addition to the T1-weighted acquisitions, 10 samples have diffusion-weighted 
MRI scans from 1,946 participants, and 9 samples have T2-weighted structural scans from 
1,836 participants. Table 4 lists the scanners and primary scan parameters for each sample. 
Full scan acquisition parameters are provided in the Supplementary Materials. 
3.5. SNP genotype data 
As detailed in the Supplementary Materials, 15 of the 19 samples had previously 
acquired raw SNP genotype data from 7,478 participants (66.4%). For 10 samples, only a 
proportion of participants had been genotyped. Four of the 19 samples had genomic DNA from 
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978 participants (8.7%), of which 947 (8.4%) participants had sufficient DNA quality and quantity 
for genotyping on the Illumina Infinium PsychArray at the central site. Table 1 lists the SNP 
arrays used for each sample. Supplementary Table 1 lists the number of genotyped 
participants in each sample and Supplementary Table 2 provides the demographic and clinical 
characteristics. Of the total 8,425 participants with genotype data, 164 participants were 
excluded during quality control analyses due to low (<98%) genotype call rate, resulting in 8,261 
participants with genotype data suitable for imputation (4,102 patients, 3,850 controls, 309 
FHR). Further quality control and imputation procedures will be described elsewhere. The mean 
call rate across the cleaned dataset is 99.8% (range 99.3%-99.9%). The sample collection has 
80% power to detect a genetic variant that explains 0.5% of the variance of a phenotype at a 
genome-wide significant alpha = 5x10-8.  
The ancestry breakdown based on genotype data is 70.7% European (2910 patients, 
2758 controls, 287 FHR), 19.1% East Asian (624 patients, 982 controls, 1 FHR), 7.2% African 
(456 patients, 114 controls, 36 FHR), 2.0% American (predominantly Latino; 138 patients, 29 
controls, 3 FHR), and 1.0% other ancestry (54 patients, 27 controls, 3 FHR).  
 
4. Discussion 
This article provides a general description of the GENUS Consortium and its sample 
collection, which is the largest known dataset of psychosis patients, controls, and FHR 
individuals with data spanning genetics, clinical, cognitive and, for a subset, structural MRI and 
diffusion imaging. This dataset enables large-scale investigations of brain-based phenotypes. 
Due to data sharing restrictions of many of the individual samples, the full dataset is currently 
only available to external researchers through collaboration with GENUS Consortium members. 
The extent of data and large size of the GENUS dataset, as well as the breadth of expertise of 
the GENUS Consortium members, provide a host of opportunities for analyses. For example, 
examining sex differences in disease-related phenotypes is an important but often overlooked 
aspect of psychiatric studies (Goldstein et al., 2013) that can be addressed with this large, well-
phenotyped sample collection. 
The GENUS Consortium differs in several aspects from other large-scale efforts 
investigating the genetic architecture of cognition and neuroanatomy relevant to psychosis (e.g., 
COGENT, ENIGMA, B-SNIP, Brain Genomics Superstruct Project, Philadelphia 
Neurodevelopmental Cohort) (Franke et al., 2016; Germine et al., 2016; Holmes et al., 2015; 
Lee et al., 2016; Lencz et al., 2014; Tamminga et al., 2013). A key difference is that many other 
studies do not have data for both cognition and brain structure modalities from the same 
participants. Bridging multiple brain phenotype modalities, as in the GENUS sample collection, 
is important for heterogeneous disorders such as schizophrenia that are defined by diverse 
symptoms and abnormalities whose relationships are mostly unknown. Another difference is the 
GENUS subject-level data are stored at the central site, allowing for stringent quality control and 
site comparability analyses, and the option for mega-analyses across the entire dataset, 
whereas some other studies are limited to meta-analysis of results generated by each site 
separately. 
A major strength of the GENUS sample collection is the existence of extensive data 
across patients, controls, and FHR individuals that enable analyses of genetic effects in multiple 
diagnostic groups. While informative genetic findings are emerging from large healthy cohorts, 
this is currently lacking in psychosis cohorts, and it remains unclear whether genetic factors 
influencing brain structure and function in healthy cohorts have the same effect in psychiatric 
patients. The GENUS Consortium analyses will initially focus on relating schizophrenia genetic 
risk variants identified by prior GWAS with the cognitive and brain structural phenotypes 
available in this sample collection. While the ENIGMA Consortium did not detect significant 
effects of schizophrenia genetic risk variants on subcortical volumes in mixed diagnosis and 
healthy individuals (Franke et al., 2016), a study of cortical thickness and surface area reported 
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that a substantial proportion (30-45%) of the heritability is explained by schizophrenia genetic 
risk variants (Lee et al., 2016). This suggests that some brain structural measures may be more 
genetically related to schizophrenia than others, or that genetic relationships differ in diseased 
and healthy brain. In addition, GWAS of cognitive performance and brain regional volumes have 
detected novel genetic associations (Adams et al., 2016; Davies et al., 2015; Hibar et al., 2015; 
Trampush et al., 2017) that could be further investigated in the GENUS sample collection. 
  Regarding genetic analyses, the GENUS sample collection is best suited for 
characterizing SNPs, polygenic factors, and pathways identified by GWAS (e.g., PGC GWAS 
mega-analyses)PGC Schizophrenia Working Group (2014) for effects on brain-based 
phenotypes, or replicating findings from other genetic studies of cognition or brain structure. 
Due to the small effect sizes of common genetic variants, our dataset is not well powered for 
GWAS discovery. SNP-based heritability approaches (e.g., GCTA) require approximately 4000 
subjects for 80% power to estimate heritability as low as 20% (Visscher et al., 2014), a 
reasonable assumption for cognitive and brain volume traits (Franke et al., 2016; Trampush et 
al., 2017); therefore, some of our phenotypes (e.g. letter-number span tests, Table 3; WAIS 
Digit Symbol Coding, Table S3) are suitable for this approach. Rare variant association studies 
require enormous samples for adequate statistical power (Auer and Lettre, 2015; Zuk et al., 
2014), therefore our dataset is not sufficient on its own for such analyses. The availability of 
multiple phenotypes enables a breadth of analyses, with the caveat that significance thresholds 
must be adjusted for multiple testing, although accounting for correlations between phenotypes 
or other data reduction methods could reduce the multiple testing burden, allowing for more 
lenient thresholds. The statistical power of our dataset could also be maximized by merging 
phenotypes into one phenotype, such as Spearman’s ‘g’, in which data from many 
neuropsychological tests are used to derive a single measure of general cognitive ability 
(Spearman, 1904).”  
  There are considerable challenges to combining data acquired by many research 
groups. The heterogeneity in the data collected and the protocols used by each group requires 
careful harmonization of the data to maximize comparability between the samples and minimize 
confounds. Our harmonization approaches will be described in greater detail in subsequent 
data-based articles. Briefly, we are applying methods that use controls from each sample to 
standardize the data (i.e., generate Z scores), as has been reported for neuropsychological data 
(Toulopoulou et al., 2010) and structural MRI data (Segall et al., 2009; Wilke et al., 2014). 
Further, variability in multi-site imaging data due to different scanner models and field strengths, 
acquisition protocols, and image segmentation methods (Han et al., 2006) can be minimized by 
processing all scans using a consistent segmentation routine, which enables detection of subtle 
effects (Fennema-Notestine et al., 2007), including gray matter loss in schizophrenia datasets 
(Segall et al., 2009). Regarding clinical data, positive and negative symptom data can be 
converted between the PANSS and SANS/SAPS, the most common clinical scales in our 
dataset, using regression-based equations (van Erp et al., 2014). As for the limited medication 
dosage information of our dataset, this can be addressed partially by confirming findings from 
the full cohort in the subset with medication data to rule out medication confounds. We are 
harmonizing the genotype data from various SNP arrays by imputing genotypes based on a 
reference panel to generate a common set of SNPs across all samples, an accepted approach 
in the field (PGC Schizophrenia Working Group, 2014). Although heterogeneous data collected 
by multiple sites is not ideal, the large volume of available legacy data with deep phenotypic and 
genotype information warrants maximizing its use by generating one merged dataset that has 
far greater statistical power than the individual samples.  
  In summary, the GENUS Consortium sample collection is a valuable resource that builds 
upon previous efforts by individual research groups and complements other psychosis datasets. 
This high-powered sample collection integrates measures of brain structure, cognition, and 
genetics for studying the biological basis of psychosis through original analyses and 
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collaborative replication studies. There will be the opportunity for multiple publications from 
these data, including articles focusing on harmonization and genetic analyses of the cognitive 
data and imaging data, and publications that incorporate multi-modal data. The rich phenotypic 
data are expected to provide new insights into neural functions that are disrupted in psychosis. 
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Table 1. Description of the GENUS Consortium Sample Collection. 
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164K chip 741 0 0 73.6 54.7 
 --- --- --- --- --- 
CIDAR/VA Boston Center for Intervention 
Development and Applied 
Research / VA Healthcare System 
Boston, USA Illumina OmniExpress 
76 107 6 68.8 60.0 
 
69 102 6 67.8 58.8 
COGS-UK Cognition and Genetics in 
Schizophrenia & Bipolar Disorder 
Cardiff, UK Illumina Infinium 
OmniExpressExome-8 843 0 0 58.8 97.4 
 --- --- --- --- --- 
GAP Genetics and Psychosis First –
Episode Study 
London, UK Illumina HumanCore-24 Exome 
BeadChip 164 160 0 59.6 46.8 
 
132 94 0 56.2 35.0 
IMH-
SIGNRP 
Institute of Mental Health –
Singapore Imaging Genetics and 
Neuropsychological Research in 
Psychosis 
Singapore Illumina Human OmniZhongHua-8; 
Illumina Human1M-Duo; Affymetrix 
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MGH Massachusetts General Hospital Boston, USA Illumina Infinium PsychArray* 
433 0 0 72.3 68.7 
 
61 123 0 64.8 73.1 
NEFS New England Family Study Boston, USA Illumina Infinium PsychArray* 
83 151 33 44.6 86.2 
 
72 155 20 54.6 89.9 
PAGES Phenomics and Genomics Sample Munich, 
Germany 
Illumina OmniExpress; Illumina 
HumanHap300 210 1,341 0 50.0 99.6 
 --- --- --- --- --- 
PHRS Pittsburgh High Risk Study Pittsburgh, USA Illumina Infinium PsychArray* 0 53 80 45.1 51.1  0 46 70 44.0 54.3 
TCD/NUIG Trinity College Dublin / National 
University of Ireland, Galway 
Multi-site, 
Ireland 
Affymetrix 6.0; Illumina HumanCore 
Exome 904 330 0 60.3 99.9 
 
175 312 0 58.8 99.8 
UMCU-SZ1 University Medical Center Utrecht  
– Schizophrenia Study 1 
Utrecht, 
Netherlands 
Illumina HumanHap550; Illumina 
Infinium OmniExpressExome-8 197 143 0 68.3 98.6 
 
159 157 0 69.3 99.1 
UMCU-SZ2 University Medical Center Utrecht 
– Schizophrenia Study 2 
Utrecht, 
Netherlands 
Illumina HumanHap550; Affymetrix 
6.0; Illumina Infinium 
OmniExpressExome-8 233 144 235 58.8 97.5 
 
184 131 212 59.0 93.6 
ZHH Zucker Hillside Hospital New York, USA Illumina OmniExpress 0 219 0 49.3 100  --- --- --- --- --- 
TOTAL    4,865 4,368 723 56.3 72.2  1,346 1,512 382 58.1 71.3 
Data in this table are based on the total GENUS sample collection; data for the subset with genotype data are provided in Supplementary Table 1. 
All samples with T1 MRI scans also have diffusion-weighted MRI scans except the PHRS, UMCU-SZ1, and UMCU-SZ2 samples. 
Population ancestry determined from genetic data (where available) or self report. 
Eur = European-derived ancestry; FHR = familial high-risk. 
*Samples genotyped at the central GENUS site. 
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Table 2. Clinical and demographic characteristics of the GENUS Consortium Sample Collection. 
 
Patients  Controls  Familial High Risk 
Statistic df p 
N Mean ± SD (Range) 
 
N 




Mean ± SD 
(Range) 
Age (years) 5,152 39.3±12.1 (13-82)  4,832 39.2±15.7 (8-86)  725 34.9±16.0 (10-85) F = 31.3 2, 10706 <1x10-10 
Education Level (years) 4,646 12.3±2.6 (1-24)  3,985 13.3±2.6 (4-26)  721 13.1±3.2 (3-24) F = 158.9 2, 9349 <1x10-10 
Premorbid IQ 3,130 97.0±15.5 (44-145)  1,352 107.2±10.6 (62-145)  83 105.1±16.0 (45-134) F = 248.9 2, 4562 <1x10-10 
Current IQ 1,897 93.8±18.1 (47-155)  2,779 113.4±14.9 (67-161)  602 105.1±15.6 (58-152) F = 823.4 2, 5275 <1x10-10 
Illness Duration (years) 4,057 14.5±11.4 (<1-58)  --- ---  --- --- --- --- --- 
Age at Onset (years) 4,074 24.5±8.2 (3-66)  --- ---  --- --- --- --- --- 
Global Assessment of Functioning 1,780 59.8±15.9 (11-100)  --- ---  --- --- --- --- --- 
PANSS Positive symptoms 2,868 16.4±7.3 (7-47)  --- ---  --- --- --- --- --- 
PANSS Negative Symptoms 2,865 16.7±7.1 (6-43)  --- ---  --- --- --- --- --- 
PANSS General Symptoms 2,874 32.0±11.5 (0-78)  --- ---  --- --- --- --- --- 
SAPS Positive Symptoms 1,983 8.1±13.0 (0-121)  --- ---  --- --- --- --- --- 
SANS Negative Symptoms 2,202 13.9±17.7 (0-103)  --- ---  --- --- --- --- --- 
Antipsychotic dose – current CPZEQ 3,130 389.9±410.7 (0-5,000)  --- ---  --- --- --- --- --- 
Antipsychotic dose – lifetime average CPZEQ 1,404 338.0±365.9 (0-3,125)  --- ---  --- --- --- --- --- 
 N %  N %  N %    
Sex (male / female; % male) 3,384 / 1,770  65.6 
 
2,394 / 2,438  49.5 
 317 / 
408 
43.7 χ2 = 319.1 2 <1x10-10 
Antipsychotic medication exposure            
Atypical 2,067 48.0  --- ---  --- --- --- --- --- 
Typical 409 9.5  --- ---  --- --- --- --- --- 
Both Typical and Atypical 545 12.7  --- ---  --- --- --- --- --- 
Naïve / None 471 10.9  --- ---  --- --- --- --- --- 
Unknown Class 422 9.0  --- ---  --- --- --- --- --- 
No information 391 9.8  --- ---  --- --- --- --- --- 
Diagnosis            
Schizophrenia 4,066 78.9  --- ---  --- --- --- --- --- 
Schizoaffective Disorder 454 8.8  --- ---  --- --- --- --- --- 
Schizophreniform Disorder 93 1.8  --- ---  --- --- --- --- --- 
Bipolar Psychosis 338 6.6  --- ---  --- --- --- --- --- 
Other Psychosis 204 4.0  --- ---  --- --- --- --- --- 
Ancestral Population         χ2 = 567.6 12 <1x10-10 
European 3,397 71.7  635 70.3  3,697 76.5 --- --- --- 
East Asian 1,109 13.5  3 23.0  697 12.3 --- --- --- 
African 152 9.8  54 3.2  507 6.8 --- --- --- 
American (Predominantly Latino) 30 2.7  3 0.6  140 1.3 --- --- --- 
South Asian 35 1.0  7 0.7  49 0.9 --- --- --- 
Mixed 8 0.4  0 0.2  18 0.2 --- --- --- 
No information 101 0.9  23 2.1  46 2.1    
Handedness (right / other; % right-handed) 2,254 / 272 89.2  2,313 / 271 89.5  609 / 68 89.9 χ2 = 0.32 2 0.85 
Data in this table are based on the total GENUS sample collection; data for the subset with genotype data are provided in Supplementary Table 2. 
CPZEQ = chlorpromazine 100 mg equivalent; df = degrees of freedom; PANSS = Positive and Negative Syndrome Scale; SANS = Scale for the Assessment of Negative Symptoms; SAPS = Scale for the 
Assessment of Positive Symptoms; SD = Standard Deviation
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Table 3. Core neuropsychological tests available for GENUS Consortium samples. 
 Attention / Processing Speed Attention / Vigilance Working Memory –  
verbal 
Working Memory – 
non-verbal 
















CAMH RBANS x* RBANS 
Semantic/ 
COWAT 
  UMD* RBANS 
Digit Span 
  RBANS RBANS  
CATIE   Category 
Instances/ 
COWAT 
x*  UMD*   SDRT HVLT   
CIDAR-VA BACS* x* MCCB* x* ACPT UMD*  WMS-III*  HVLT-R* WMS-III 
or CMS 
 
COGS-UK BACS* x* MCCB* x*  UMD*  WMS-III*  HVLT-R*   
GAP WAIS-III x* Semantic/ 
COWAT 




 WMS-III  
IMH-
SIGNRP 




   BACS Digit 
Sequencing 
  BACS   
IMH-
STCRP 
BACS*  BACS 
Category 
Instances 
x*   BACS Digit 
Sequencing 
  BACS   
































L&R BACS* x* MCCB* x* ACPT UMD*  WMS-III*  HVLT-R* WMS-III  
MCIC  x* D-KEFS 
Semantic/ 
Phonemic 
  WAIS-III    HVLT-R* WMS-III  
MGH WAIS-III  Semantic/ 
COWAT 
x*  WAIS-III WAIS-III 
Digit Span / 
Arithmetic 
  CVLT   
NEFS WAIS-R  COWAT  ACPT  WAIS-R 
Digit Span 









 3-7 CPT  WAIS-R-DE 
Digit Span / 
Arithmetic 





PHRS   MAE 
Semantic/ 
Phonemic 
x* A-X CPT    Cogtest 
SWM 
Cogtest   
TCD/NUIG  x* COWAT x* 1-9 CPT  WMS-III   CANTAB 
SWM 
/ n-back 
CVLT-SF WMS-III  
UMCU-
SZ1 
  MAE 
Semantic/ 
Phonemic 





   H-Q CPT  WAIS-III-NL 
Arithmetic 
  AVLT   
ZHH BACS* x* MCCB* / 
COWAT 
x*  UMD* WAIS-R 
Digit Span 
WMS-III* n-back HVLT-R*   
N patients 3,488 1,549 3,956 2,337 703 2,895 1,866 1,097 1,644 3,488 1,452 388 
N controls 3,535 1,116 2,826 1,410 1,025 1,080 3,248 610 904 2,519 1,017 705 
N FHR 396 196 280 119 381 79 347 76 89 384 82 177 
N total 7,419 2,861 7,062 3,866 2,109 4,054 5,461 1,783 2,637 6,391 2,551 1,270 
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Table 3. Core neuropsychological tests available for GENUS Consortium samples. --- Continued 
 
 Visual Learning & Memory Reasoning / Problem Solving Visuo-spatial Ability Verbal Ability 
Sample BVMT-R* Other TMT-B WCST Other Block Design Other Vocabulary Other 
CAMH  RBANS 
Figure Recall 
x  Stroop  RBANS JOLO / 
Figure Copy  
  
CATIE    64-C WISC-III 
Mazes 
    
CIDAR-VA BVMT-R*   64-C NAB Mazes* WASI  WASI D-KEFS 
Proverbs 
COGS-UK BVMT-R*    NAB Mazes*     
GAP  WMS-III 
VisRep 
x  CANTAB SOC WAIS-III WAIS-III MR  WAIS-III INF 
IMH-SIGNRP     BACS TOL     
IMH-STCRP    64-P BACS TOL  WASI MR / 
Benton JOLO  
  
KCL-MFS  WMS-R 
VisRep 
x  CANTAB IDED WAIS-R WAIS-R OA / 
PA / PC 
WAIS-R WAIS-R 
COM 
/ INF / SIM 
KCL-MTS  WMS-R-UK 
VisRep / 
VisPA 
x  CANTAB IDED WAIS-III-UK WAIS-III-UK 
OA / PA / PC 
WAIS-III-UK WAIS-III-UK 
COM  
/ INF / SIM 
L&R BVMT-R*   64-C NAB Mazes* WASI  WASI D-KEFS 
Proverbs 
MCIC  BVRT / 
WMS-III Faces 
x  TOL WAIS-III  WAIS-III WAIS-III 
SIM 
MGH    128-C / 
64-C 
 WAIS-III WAIS-III MR / 
OA / PA / PC 
WAIS-III WAIS-III 
COM 
/ INF / SIM 
NEFS  WMS-III Faces / 
Rey CFT Recall 
 128-P Stroop WAIS-R WAIS-R PA / 
Rey CFT Copy 
WAIS-R WAIS-R 
COM 
/ INF; RAN 




x 128-C TOL-DE WAIS-R-DE WAIS-R-DE 
OA / PA / PC 
WAIS-R-DE WAIS-R-DE 
COM 
/ INF / SIM 
PHRS  CNB VOLT  128-P Cogtest 
Go-No-Go 
    
TCD/NUIG  WMS-III Faces / 
CANTAB PAL 










UMCU-SZ2     NAB Mazes* 
/ RST 
WAIS-III-NL   WAIS-III-NL 
INF 
ZHH BVMT-R*  x 128-P NAB Mazes* 
/ Stroop 
    
N patients 897 1,604 836 1,376 3,555 2,260 1,615 1,754 2,048 
N controls 328 1,628 1,408 835 2,781 2,744 3,131 2,425 2,617 
N FHR 48 317 145 134 350 522 33 285 567 
N total 1,273 3,549 2,389 2,345 6,686 5,526 4,779 4,464 5,232 
*MATRICS test. 
References for all neuropsychological tests are provided in the Supplemental Materials. 
Data in this table are based on the total GENUS sample collection (genotyped plus ungenotyped). 
Abbreviations: 128-P, 128-C = 128-card paper, computerized version; 64-P, 64-C = 64-card paper, computerized version; ACPT = Auditory CPT; AVLT 
= Auditory Verbal Learning Test; BACS = Brief Assessment of Cognition in Schizophrenia; BVMT-R= Brief Visuospatial Memory Test-Revised; BVRT = 
Benton Visual Retention Test; CANTAB = Cambridge Neuropsychological Test Automated Battery; CFT = Complex Figure Test; CMS = Children’s 
Memory Scale; CNB = Computerized Neurocognitive Battery; COWAT = Controlled Oral Word Association Test; CPT(-IP) = Continuous Performance 
Test (Identical Pairs); CVLT(-SF) = California Verbal Learning Test (Short Form); DE = German version; D-KEFS = Delis–Kaplan Executive Function 
System; FigMem = Figural Memory; HVLT = Hopkins Verbal Learning Test; IDED = Intra-Extra Dimensional Set Shifting; JOLO = Judgment of Line 
Orientation; MAE = Multilingual Aphasia Examination; MCCB = MATRICS Consensus Cognitive Battery; NAB = Neuropsychological Assessment 
Battery; NL = Dutch version; PAL = Paired Associates Learning; RAN = Rapid Automatized Naming; RBANS = Repeatable Battery for the Assessment 
of Neuropsychological Status; RST = Response Shifting Task; RVIP = Rapid Visual Information Processing; SART = Sustained Attention to Response 
Task; SDRT = Spatial Delayed Response Task; SOC = Stockings of Cambridge; SWM = Spatial Working Memory; TOL = Tower of London; TMT-A, B = 
Trail Making Test Part A, B; UK = British version; UMD = University of Maryland; VerbPA = Verbal Paired Associates; VisMemSpan = Visual Memory 
Span; VisPA = Visual Paired Associates; VisRep = Visual Reproduction; VLMT = Verbal Learning and Memory Test; VLT = Verbaler Lern Test; VOLT = 
Visual Object Learning Test; WAIS = Wechsler Adult Intelligence Scale (Subtests: COM = Comprehension; INF = Information; MR = Matrix Reasoning; 
OA = Object Assembly; PA = Picture Arrangement; PC = Picture Completion; SIM = Similarities); WASI = Wechsler Abbreviated Scale of Intelligence; 




Table 4. MRI scan parameters for GENUS Consortium samples. 
Sample Magnetic 
Field Strength 











CAMH 1.5T GE Echospeed IR-SPGR 0.78 x 0.78 x 1.5 23 1000 2.6 x 2.6 x 2.6 
CIDAR-VA 3T GE Signa HDxt 
Echospeed 
IR-SPGR 1.0 x 1.0 x 1.0 51 900 1.67 x 1.67 x 1.7 
 3T Siemens Trio Tim MP-RAGE 1.0 x 1.0 x 1.33 60 700 2.0 x 2.0 x 2.0 
GAP 3T GE Signa HDx MP-RAGE 1.01 x 1.01 x 1.2 32 1300 2.4 x 2.4 x 2.4 
IMH-SIGNRP 3T Philips Intera Achieva TFE 0.9 x 0.9 x 0.9 15 800 0.9 x 0.9 x 3.0 
KCL-MTS 1.5T GE Signa Advantage SPGR 0.78 x 0.78 x 1.5 64 1300 2.5 x 2.5 x 2.5 
 1.5T GE Signa Advantage SPGR 0.78 x 0.78 x 1.5 64 1300 2.5 x 2.5 x 2.5 
L&R 3T Siemens Trio Tim MP-RAGE 1.0 x 1.0 x 1.0 60 700 2.0 x 2.0 x 2.0 
MCIC 1.5T Siemens Sonata GRE 0.7 x 0.7 x 1.5 60 700 2.0 x 2.0 x 2.0 
 3T Siemens Trio Tim MP-RAGE 0.625 x 0.625 x 1.5 12 1000 2.0 x 2.0 x 2.0 
 1.5T Siemens Sonata GRE 0.625 x 0.625 x 1.5 12 1000 2.0 x 2.0 x 2.0 
MGH 3T Siemens Trio Tim ME-MP-RAGE 1.2 x 1.2 x 1.2 6 1000 1.375 x 1.375 x 3.0 
 3T Siemens Trio Tim MP-RAGE 1 x 1 x 1.3 --- --- --- 
NEFS 1.5T Siemens Avanto MP-RAGE 1.0 x 1.0 x 1.33 60 700 2.0 x 2.0 x 2.0 
 1.5T Siemens Sonata MP-RAGE 1.0 x 1.0 x 1.33 6 600 2.0 x 2.0 x 2.0 
 1.5T Siemens Sonata MP-RAGE 1.0 x 1.0 x 1.5 --- --- --- 
 3T Siemens Trio Tim MP-RAGE 1.0 x 1.0 x 1.33 60 700 2.0 x 2.0 x 2.0 
 1.5T GE Genesis Signa EFGRE 0.94 x 0.94 x 1.5 --- --- --- 
PHRS 1.5T GE Genesis Signa SPGR 1.25 x 1.25 x 1.5 --- --- --- 
TCD/NUIG 3T Philips Intera Achieva TFE 0.9 x 0.9 x 0.9 15 800 1.75 x 1.75 x 2.2 
 1.5T Siemens Magnetom 
Symphony 
MP-RAGE 0.45 x 0.45 x 0.9 --- --- --- 
UMCU-SZ1 1.5T Philips NT Intera FFE 1.0 x 1.0 x 1.2 --- --- --- 
UMCU-SZ2 1.5T Philips Achieva FFE 1.0 x 1.0 x 1.2 --- --- --- 
DW-MRI = Diffusion-Weighted MRI; EFGRE = Enhanced Fast Gradient Echo; FFE = Fast Field Echo; GE = General Electric; GRE = Gradient Recalled Echo; (IR-)SPGR = 
(Inversion Recovery) Spoiled Gradient Recalled; (ME-)MP-RAGE = (Multi-Echo) Magnetization Prepared Rapid Acquisition Gradient Echo; TFE = Turbo Field Echo 
 
 
